Publish with Us Search
Publish with Us

Targeted Cancer Therapy Connect

ISSN: 3105-3629

Eyad Elkord
Editor-in-Chief

Eyad Elkord
Editor-in-Chief

View Profile

Targeted Cancer Therapy Connect is a peer-reviewed, open-access journal dedicated to advancing precision and targeted approaches in cancer treatment. The journal publishes innovative research that deepens understanding of the molecular and immunological mechanisms driving cancer progression and therapeutic response. This open-access journal follows a continuous publication model and is licensed under Creative Commons Attribution 4.0 (CC BY 4.0).

Volumes 1
Articles 9
Volume: 1, 2025
Submit Article Join Our Editorial Board Become a Reviewer
Download Flyer
Volumes

SCIFINITI ALERT!

Subscribe for research updates and exclusive content straight to your inbox

Open Access Policy:
All articles published in the journal Targeted Cancer Therapy Connect are made accessible through an open-access model, released under the CC BY license. This license facilitates the unrestricted dissemination of articles, encouraging widespread sharing and utilization of valuable research contributions.

Publication Charges:
There will be no article processing charges (APCs) for submissions made by December 2025, and all articles will be available as Open Access.

Subject Categories:
Targeted Cancer Therapy, Immunotherapy, Precision Oncology

Article Template:

You are encouraged to use the template to format your article according to our guidelines. However, this is not mandatory, as our layout team will ensure all necessary adjustments are made after acceptance and prior to final publication.

Download Template 

Target Audience:
Targeted Cancer Therapy Connect provides a platform for researchers, clinicians, and industry experts to share insights, foster collaboration, and explore emerging directions in targeted and immune-based cancer treatment.

Ethics Statement:

All articles published by Targeted Cancer Therapy Connect adhere strictly to the ethical guidelines suggested by the Committee on Publication Ethics (COPE). We execute a stringent peer-review procedure that meticulously assesses the originality, quality, and precision of the research we disseminate. We employ advanced tools to scrutinize the legitimacy of submitted content and maintain a firm zero-tolerance stance toward instances of plagiarism, data manipulation, or inappropriate authorship. For further details, please review our comprehensive Publication Ethics and Integrity Guidelines.

Insights

More Insights

31 Days

Time to First Peer Review Decision

52 Days

Time to Final Acceptance

7 Days

Acceptance to First Online

Recent Updates

All Updates
Welcoming Dr. Eyad Elkord to Cancer Immunology Connect
2024-08-19
Announcing the Launch of Cancer Immunology Connect
2024-08-15

Recent Articles

All Articles
Mini-Review

Available Online: 23 Dec 2025

Covalent BH3-Mimetics and PROTACs Targeting BCL2 Family for Precision Apoptosis Induction

Volume 1

The BCL2 family of proteins serves as a central regulator of mitochondrial outer membrane permeabilization (MOMP) and intrinsic apoptosis, with anti-apoptotic members such as BCL2, BCL-XL, and MCL1 frequently overexpressed in cancers to evade programmed cell death. Traditional BH3 mimetics, like venetoclax and navitoclax, have revolutionized treatment for hematologic malignancies by competitively inhibiting these pro-survival proteins, yet they face challenges..

https://doi.org/Registering DOI
Review Article

Published: 17 Jun 2025

The Intratumor Microbiome: An Untapped Avenue for Translational Applications in Cancer Immunotherapeutics

Volume 1

https://doi.org/10.69709/CIConnect.2025.154988
Research Article

Published: 15 Apr 2025

Association of Expression of Immune Checkpoints in Tumor-Infiltrating CD4+ T Lymphocytes with Disease-Free Survival in Colorectal Cancer Patients

Volume 1

https://doi.org/10.69709/CIConnect.2025.119991
Research Article

Published: 21 Mar 2025

Characteristics of Tumor Infiltrating Lymphocytes in Patients with Benign and Malignant Sinonasal Neoplasms

Volume 1

Introduction. Tumor infiltrating lymphocytes are a major component of sinonasal neoplasms, actively populating tumor tissue, yet their role remains poorly understood. The aim is to characterize subsets and functional profiles of tumor infiltrating lymphocytes in patients with benign and malignant sinonasal tumors. Materials and methods. Tumor infiltrating lymphocytes were isolated from the biopsy material of 58 patients: 18 with sinonasal..

https://doi.org/10.69709/CIConnect.2025.133891
Share
Help